IS Pharma plc, through its subsidiaries, develops, acquires, and commercializes various pharmaceutical and medical devices focusing on the areas of critical care, oncology, and neurology in the United Kingdom and internationally. The company's commercial product line includes Volplex, a sterile, apyrogenic plasma substitute solution for intravenous infusion; Cryogesic and Dermogesic, vapo-coolant sprays for topical local analgesia prior to minor invasive procedures; Mysoline, an oral treatment for various forms of epilepsy and essential tremor; Aloxi, an antagonist used for the prevention of nausea and vomiting; and Isoplex, a succinylated gelatin plasma substitute in a balanced electrolyte solution providing fluid volume replacement and improvement in electrolyte balance. Its late stage development products comprise Haemopressin, an injectable product for treatment of bleeding oesophageal varices; Acoranil, a liquid presentation of antidepressant for patients unable to take tablets; AquiHex, a solution to help reduce hospital acquired infections; and Gentispray, an ear spray combination of an antibiotic and steroid for the treatment of otitis externa. The company's partnered product line consists of OptiFlo, various catheter irrigation solutions, distributed by Bard Ltd.; ContiSol, a brand of catheter irrigation solutions; and Micelle Nanotechnology, a drug delivery system in development, which is licensed to Plethora Solutions Holdings PLC for the treatment of interstitial cystitis. IS Pharma plc was formerly known as Maelor plc and changed its name to IS Pharma plc in April 2008. The company is based in Chester, the United Kingdom.